

## Professor David Mutimer

Professor of Clinical Hepatology and Honorary Consultant Hepatologist to the QE Hospital Liver and Hepatobiliary Unit

School of Immunity and Infection

### Contact details

**Telephone** [+44 \(0\)121 371 4660](tel:+441213714660) (tel: [+44 121 371 4660](tel:+441213714660))

**Email** [david.mutimer@uhb.nhs.uk](mailto:david.mutimer@uhb.nhs.uk) (<mailto:david.mutimer@uhb.nhs.uk>)

School of Immunity and Infection  
College of Medical and Dental Sciences  
University of Birmingham  
Edgbaston  
Birmingham  
B15 2TT  
UK

### About

David Mutimer is Professor of Clinical Hepatology at the University of Birmingham and Honorary Consultant Hepatologist to the Queen Elizabeth Hospital Liver and Hepatobiliary Unit, Birmingham.

### Qualifications

- MBBS (Melbourne 1980)
- MD (Melbourne 1998)

### Biography

David graduated from Monash University, Melbourne in 1980 and commenced specialist training in Internal Medicine and Gastroenterology in Melbourne.

In 1986 he came to the UK and worked as research fellow at the University of Newcastle-upon-Tyne from 1986-89. From 1987-89 he held the British Digestive Foundation Amelia Waring Research Fellowship.

In 1989 he moved to the Birmingham Queen Elizabeth Hospital Liver Unit, and has worked there since that time. In 1996 he was appointed Senior Lecturer then Reader in Hepatology (B'ham University) and Honorary Consultant Hepatologist to the Liver and Hepatobiliary Unit. He was Clinical Service Lead for Hepatology at the Queen Elizabeth Hospital from 2000 to 2010.

In the field of hepatitis infection, he has focused on antiviral treatment, drug resistance, epidemiology and natural history of infection. In the field of liver transplantation, his principal interests have included the treatment and prevention of recurrent viral hepatitis and opportunistic infections.

He is a fellow of the Royal College of Physicians of England and Australasian College of Physicians. He acts as adviser to the Department of Health on issues related to viral hepatitis and liver transplantation, and is a founder and trustee of the charity, *Hepatitis B Foundation UK*.

He has published more than 100 original and invited articles in peer-reviewed journals. He was associate editor of *Gut* (2007-9) and is now a member of the editorial boards of *Gut*, *the Journal of Hepatology*, *Liver Transplantation*, and *Alimentary Pharmacology and Therapeutics*.

### Teaching

#### TEACHING ACTIVITY

- Birmingham Medical Undergraduates - [Medicine and Surgery MBChB \(/undergraduate/courses/med/medicine.aspx\)](#)
- MSc
- [BMed Sci \(/undergraduate/courses/med/medical-sci.aspx\)](#)
- Medical Post-graduate teaching.

### Research

#### RESEARCH ACTIVITY

Chief investigator and/or Principal Investigator in a number of studies, principally involving antiviral treatment.

David is one of the PI's for the Birmingham NIHR BRU in Liver Disease.

### Other activities

#### CLINICAL ACTIVITY / NHS AFFILIATION

- Clinical Service Lead for Liver Medicine, Birmingham QE Hospital Liver and Hepatobiliary Unit

### Publications

**Thurairajah PH, Thorburn D, Hubscher S, White A, Lai WK, O'Donnell K, Mutimer DJ.** (<http://www.ncbi.nlm.nih.gov/sites/>?)

Db=pubmed&Cmd=ShowDetailView&TermToSearch=17509097&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\_ResultsPanel.Pubmed\_RVDocSum) Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007 Jun 1;25(11):1293-300.

**Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer DJ.** ([http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17258882&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17258882&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum)) Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol. 2007 Sep;33(7):868-73.

Freshwater DA, Dudley T, Cane P, Mutimer DJ. **Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study.** ([http://www.ncbi.nlm.nih.gov/pubmed/18431229?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_DefaultReportPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/pubmed/18431229?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)) Transplantation. 2008 Apr 27;85(8):1105-11.

Bhattacharya S, O'Donnell K, Dudley T, Kennefick A, Osman H, Boxall E, Mutimer D. **Ante-natal screening and post-natal follow-up of hepatitis B in the West Midlands of England.** ([http://www.ncbi.nlm.nih.gov/pubmed/18281704?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_DefaultReportPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/pubmed/18281704?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)) QJM. 2008 Apr;101(4):307-12.

Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Carman W. **The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting.** ([http://www.ncbi.nlm.nih.gov/pubmed/18203658?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_DefaultReportPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/pubmed/18203658?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)) J Clin Virol. 2008 Apr;41(4):243-54.

Freshwater DA, O'Donnell K, Mutimer DJ. **Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy.** ([http://www.ncbi.nlm.nih.gov/pubmed/18184194?ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_DefaultReportPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/pubmed/18184194?ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)) J Viral Hepat. 2008 Feb;15(2):115-9.

Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D. **Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation.** ([http://www.ncbi.nlm.nih.gov/pubmed/18161844?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed\\_ResultsPanel.Pubmed\\_DefaultReportPanel.Pubmed\\_RVDocSum](http://www.ncbi.nlm.nih.gov/pubmed/18161844?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)) Liver Transpl. 2008 Jan;14:81-7.

---

[Privacy](#) | [Legal](#) | [Cookies and cookie policy](#) | [Accessibility](#) | [Site map](#) | [Website feedback](#) | [Charitable information](#)

© University of Birmingham 2015

